Subscribe to RSS
DOI: 10.1055/s-0031-1297929
The Conundrum of Relapse in STAT-C Therapy: Does HCV Play the Red Queen or Rip Van Winkle?
Publication History
Publication Date:
21 December 2011 (online)

ABSTRACT
New treatments for chronic hepatitis C combining direct-acting antivirals (DAAs) with pegylated interferon and ribavirin (PEG-IFN/RBV) have dramatically increased the number of patients whose viral load declines to undetectable levels early in treatment. Most go on to achieve a sustained virologic response, but some patients who maintain undetectable levels of virus throughout treatment later relapse during follow-up. These data suggest that hepatitis C virus (HCV) genomes may persist in form(s) that are refractory to eradication by DAAs and PEG-IFN/RBV. Here we examine the molecular biology of HCV replication and review the clinical virology of relapse for clues as to how the virus might survive months of antiviral therapy to later reappear when treatment is withdrawn.
KEYWORDS
Hepatitis C virus - direct-acting antivirals - relapse - resistance
REFERENCES
- 1
Poordad F, McCone Jr J, Bacon B R SPRINT-2 Investigators et al.
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med.
2011;
364
(13)
1195-1206
MissingFormLabel
- 2
Bacon B R, Gordon S C, Lawitz E HCV RESPOND-2 Investigators et al.
Boceprevir for previously treated chronic HCV genotype 1 infection.
N Engl J Med.
2011;
364
(13)
1207-1217
MissingFormLabel
- 3
Jacobson I M, McHutchison J G, Dusheiko G ADVANCE Study Team et al.
Telaprevir for previously untreated chronic hepatitis C virus infection.
N Engl J Med.
2011;
364
(25)
2405-2416
MissingFormLabel
- 4
Zeuzem S, Andreone P, Pol S REALIZE Study Team et al.
Telaprevir for retreatment of HCV infection.
N Engl J Med.
2011;
364
(25)
2417-2428
MissingFormLabel
- 5
Pawlotsky J M, Cocquerel L, Durantel D et al..
HCV research 20 years after discovery: a summary of the 16th international symposium
on hepatitis C virus and related viruses.
Gastroenterology.
2010;
138
(1)
6-12, e1–e2
MissingFormLabel
- 6
Lange C M, Sarrazin C, Zeuzem S.
Review article: specifically targeted anti-viral therapy for hepatitis C - a new era
in therapy.
Aliment Pharmacol Ther.
2010;
32
(1)
14-28
MissingFormLabel
- 7
Forestier N, Larrey D, Guyader D et al..
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir
(ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending
dose study.
J Hepatol.
2011;
54
(6)
1130-1136
MissingFormLabel
- 8
Reesink H W, Fanning G C, Farha K A et al..
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers
and hepatitis C patients.
Gastroenterology.
2010;
138
(3)
913-921
MissingFormLabel
- 9
McHutchison J G, Lawitz E J, Shiffman M L IDEAL Study Team et al.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
N Engl J Med.
2009;
361
(6)
580-593
MissingFormLabel
- 10 U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing
Document: Background Material for Boceprevir. Silver Spring, MD: U.S. Food and Drug Administration; 2011: 31
MissingFormLabel
- 11 U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing
Document for NDA 201–917 Telaprevir 375 mg Tablets. Silver Spring, MD: U.S. Food and Drug Administration; 2011: 22
MissingFormLabel
- 12 U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing
Document: Boceprevir Capsules (NDA 202–258) Briefing Document. Whitehouse Station, NJ: Merck and Co; 2011: 90
MissingFormLabel
- 13 U.S. Food and Drug Administration. US FDA Antiviral Drugs Advisory Committee Briefing
Document: Telaprevir 375-mg Film-Coated Tablet for the Treatment of Genotype 1 Chronic
Hepatitis C. Cambridge, MA: Vertex Pharmaceuticals; 2011: 147
MissingFormLabel
- 14
Ludmerer S W, Graham D J, Boots E et al..
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates
characterized by using a transient replication assay.
Antimicrob Agents Chemother.
2005;
49
(5)
2059-2069
MissingFormLabel
- 15
Le Pogam S, Seshaadri A, Kosaka A et al..
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside,
but not to nucleoside, polymerase inhibitors among untreated patients.
J Antimicrob Chemother.
2008;
61
(6)
1205-1216
MissingFormLabel
- 16 Pockros P, Jensen D, Tsai N et al.. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128)
combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim
analysis from the JUMP-C trial. Paper presented at: European Association for the Study of the Liver 46th Annual Meeting March 30–April 3, 2011. Berlin, Germany;
MissingFormLabel
- 17
van Valen L.
A new evolutionary law.
Evol Theory.
1973;
1
1-30
MissingFormLabel
- 18
Domingo E, Escarmís C, Sevilla N et al..
Basic concepts in RNA virus evolution.
FASEB J.
1996;
10
(8)
859-864
MissingFormLabel
- 19
Pham T N, Michalak T I.
Occult persistence and lymphotropism of hepatitis C viral infection.
World J Gastroenterol.
2008;
14
(18)
2789-2793
MissingFormLabel
- 20
Sumpter Jr R, Loo Y M, Foy E et al..
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus
RNA replication through a cellular RNA helicase, RIG-I.
J Virol.
2005;
79
(5)
2689-2699
MissingFormLabel
- 21
Shoukry N H, Cawthon A G, Walker C M.
Cell-mediated immunity and the outcome of hepatitis C virus infection.
Annu Rev Microbiol.
2004;
58
391-424
MissingFormLabel
- 22
Tillmann H L, Thompson A J, Patel K German Anti-D Study Group et al.
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis
C virus and jaundice.
Gastroenterology.
2010;
139
(5)
1586-1592, 1592, e1
MissingFormLabel
- 23
Walters K A, Katze M G.
Using high-throughput genomics to study hepatitis C: what determines the outcome of
infection?.
Antiviral Res.
2009;
81
(3)
198-208
MissingFormLabel
- 24
Sugano M, Hayashi Y, Yoon S et al..
Quantitation of hepatitis C viral RNA in liver and serum samples using competitive
polymerase chain reaction.
J Clin Pathol.
1995;
48
(9)
820-825
MissingFormLabel
- 25
Neumann A U, Lam N P, Dahari H et al..
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha
therapy.
Science.
1998;
282
(5386)
103-107
MissingFormLabel
- 26 Guedj J, Dahari H, Rong L et al.. New insights into the mechanism of action of interferon-alpha and BMS-790052: a multi-scale
mathematical modeling approach. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 27
Gowans EJ.
Distribution of markers of hepatitis C virus infection throughout the body.
Semin Liver Dis.
2001;
20
(1)
85-102
MissingFormLabel
- 28
Idrees M, Lal A, Malik F A et al..
Occult hepatitis C virus infection and associated predictive factors: the Pakistan
experience.
Infect Genet Evol.
2011;
11
(2)
442-445
MissingFormLabel
- 29
Carreño V, Pardo M, López-Alcorocho J M, Rodríguez-Iñigo E, Bartolomé J, Castillo I.
Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive,
serum HCV RNA-negative patients with normal alanine aminotransferase levels.
J Infect Dis.
2006;
194
(1)
53-60
MissingFormLabel
- 30
Castillo I, Rodríguez-Iñigo E, López-Alcorocho J M, Pardo M, Bartolomé J, Carreño V.
Hepatitis C virus replicates in the liver of patients who have a sustained response
to antiviral treatment.
Clin Infect Dis.
2006;
43
(10)
1277-1283
MissingFormLabel
- 31
Carreño V.
Occult hepatitis C virus infection: a new form of hepatitis C.
World J Gastroenterol.
2006;
12
(43)
6922-6925
MissingFormLabel
- 32
Chang M, Williams O, Mittler J et al..
Dynamics of hepatitis C virus replication in human liver.
Am J Pathol.
2003;
163
(2)
433-444
MissingFormLabel
- 33
Egger D, Wölk B, Gosert R et al..
Expression of hepatitis C virus proteins induces distinct membrane alterations including
a candidate viral replication complex.
J Virol.
2002;
76
(12)
5974-5984
MissingFormLabel
- 34
Moradpour D, Penin F, Rice C M.
Replication of hepatitis C virus.
Nat Rev Microbiol.
2007;
5
(6)
453-463
MissingFormLabel
- 35
Gosert R, Egger D, Lohmann V et al..
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring
subgenomic replicons.
J Virol.
2003;
77
(9)
5487-5492
MissingFormLabel
- 36
Rouillé Y, Helle F, Delgrange D et al..
Subcellular localization of hepatitis C virus structural proteins in a cell culture
system that efficiently replicates the virus.
J Virol.
2006;
80
(6)
2832-2841
MissingFormLabel
- 37
Pfeifer U, Thomssen R, Legler K et al..
Experimental non-A, non-B hepatitis: four types of cytoplasmic alteration in hepatocytes
of infected chimpanzees.
Virchows Arch B Cell Pathol Incl Mol Pathol.
1980;
33
(3)
233-243
MissingFormLabel
- 38
Schaff Z, Tabor E, Jackson D R, Gerety R J.
Ultrastructural alterations in serial liver biopsy specimens from chimpanzees experimentally
infected with a human non-A, non-B hepatitis agent.
Virchows Arch B Cell Pathol Incl Mol Pathol.
1984;
45
(3)
301-312
MissingFormLabel
- 39
De Vos R, Verslype C, Depla E et al..
Ultrastructural visualization of hepatitis C virus components in human and primate
liver biopsies.
J Hepatol.
2002;
37
(3)
370-379
MissingFormLabel
- 40
Kasprzak A, Seidel J, Biczysko W, Wysocki J, Spachacz R, Zabel M.
Intracellular localization of NS3 and C proteins in chronic hepatitis C.
Liver Int.
2005;
25
(4)
896-903
MissingFormLabel
- 41
Falcón V, Acosta-Rivero N, Chinea G et al..
Ultrastructural evidences of HCV infection in hepatocytes of chronically HCV-infected
patients.
Biochem Biophys Res Commun.
2003;
305
(4)
1085-1090
MissingFormLabel
- 42
Asselah T, Bièche I, Mansouri A et al..
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C.
J Pathol.
2010;
221
(3)
264-274
MissingFormLabel
- 43
Ferraris P, Blanchard E, Roingeard P.
Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell
membranes.
J Gen Virol.
2010;
91
(Pt 9)
2230-2237
MissingFormLabel
- 44
Reiss S, Rebhan I, Backes P et al..
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential
for integrity of the membranous replication compartment.
Cell Host Microbe.
2011;
9
(1)
32-45
MissingFormLabel
- 45
Knoops K, Kikkert M, Worm S H et al..
SARS-coronavirus replication is supported by a reticulovesicular network of modified
endoplasmic reticulum.
PLoS Biol.
2008;
6
(9)
e226
MissingFormLabel
- 46
Uchil P D, Satchidanandam V.
Architecture of the flaviviral replication complex. Protease, nuclease, and detergents
reveal encasement within double-layered membrane compartments.
J Biol Chem.
2003;
278
(27)
24388-24398
MissingFormLabel
- 47
Mackenzie J M, Jones M K, Young P R.
Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role
in viral RNA replication.
Virology.
1996;
220
(1)
232-240
MissingFormLabel
- 48
Westaway E G, Mackenzie J M, Kenney M T, Jones M K, Khromykh A A.
Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with
double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures.
J Virol.
1997;
71
(9)
6650-6661
MissingFormLabel
- 49
Quinkert D, Bartenschlager R, Lohmann V.
Quantitative analysis of the hepatitis C virus replication complex.
J Virol.
2005;
79
(21)
13594-13605
MissingFormLabel
- 50
Syed G H, Amako Y, Siddiqui A.
Hepatitis C virus hijacks host lipid metabolism.
Trends Endocrinol Metab.
2010;
21
(1)
33-40
MissingFormLabel
- 51
Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari F V.
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and
secretion.
J Virol.
2008;
82
(5)
2120-2129
MissingFormLabel
- 52
Russell R S, Meunier J C, Takikawa S et al..
Advantages of a single-cycle production assay to study cell culture-adaptive mutations
of hepatitis C virus.
Proc Natl Acad Sci U S A.
2008;
105
(11)
4370-4375
MissingFormLabel
- 53
Brimacombe C L, Grove J, Meredith L W et al..
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.
J Virol.
2011;
85
(1)
596-605
MissingFormLabel
- 54
Valli M B, Serafino A, Crema A et al..
Transmission in vitro of hepatitis C virus from persistently infected human B-cells
to hepatoma cells by cell-to-cell contact.
J Med Virol.
2006;
78
(2)
192-201
MissingFormLabel
- 55
Timpe J M, Stamataki Z, Jennings A et al..
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing
antibodies.
Hepatology.
2008;
47
(1)
17-24
MissingFormLabel
- 56
Witteveldt J, Evans M J, Bitzegeio J et al..
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.
J Gen Virol.
2009;
90
(Pt 1)
48-58
MissingFormLabel
- 57 Catanese M T, Loureiro J, Jones C T et al.. Viral and cellular determinants of HCV cell-to-cell spread. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 58
Sigal A, Kim J T, Balazs A B et al..
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.
Nature.
2011;
477
(7362)
95-98
MissingFormLabel
- 59
Hu Y, Shahidi A, Park S, Guilfoyle D, Hirshfield I.
Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive,
single-tube nested polymerase chain reaction.
Am J Clin Pathol.
2003;
119
(1)
95-100
MissingFormLabel
- 60
Sung V M, Shimodaira S, Doughty A L et al..
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C
virus in vivo and in vitro: the apoptotic effects of virus infection.
J Virol.
2003;
77
(3)
2134-2146
MissingFormLabel
- 61
Steffan A, Marianneau P, Caussin-Schwemling C et al..
Ultrastructural observations in hepatitis C virus-infected lymphoid cells.
Microbes Infect.
2001;
3
(3)
193-202
MissingFormLabel
- 62
Pham T N, Michalak T I.
Occult persistence and lymphotropism of hepatitis C virus infection.
World J Gastroenterol.
2008;
14
(18)
2789-2793
MissingFormLabel
- 63
Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M.
Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically
infected patients.
J Infect Dis.
1997;
176
(5)
1209-1214
MissingFormLabel
- 64
Boisvert J, He X S, Cheung R, Keeffe E B, Wright T, Greenberg H B.
Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication
detected only in liver.
J Infect Dis.
2001;
184
(7)
827-835
MissingFormLabel
- 65
Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A.
Differential distribution and internal translation efficiency of hepatitis C virus
quasispecies present in dendritic and liver cells.
Blood.
2003;
101
(1)
52-57
MissingFormLabel
- 66
Sansonno D, Tucci F A, Lauletta G et al..
Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia.
Clin Exp Immunol.
2007;
147
(2)
241-248
MissingFormLabel
- 67
Laskus T, Radkowski M, Jablonska J et al..
Human immunodeficiency virus facilitates infection/replication of hepatitis C virus
in native human macrophages.
Blood.
2004;
103
(10)
3854-3859
MissingFormLabel
- 68
Lerat H, Rumin S, Habersetzer F et al..
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence
of viral load, viral genotype, and cell phenotype.
Blood.
1998;
91
(10)
3841-3849
MissingFormLabel
- 69
Di Liberto G, Roque-Afonso A M, Kara R et al..
Clinical and therapeutic implications of hepatitis C virus compartmentalization.
Gastroenterology.
2006;
131
(1)
76-84
MissingFormLabel
- 70
Pham T N, Mulrooney-Cousins P M, Mercer S E et al..
Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells
during persistent occult infection.
J Viral Hepat.
2007;
14
(8)
537-548
MissingFormLabel
- 71
Radkowski M, Gallegos-Orozco J F, Jablonska J et al..
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis
C.
Hepatology.
2005;
41
(1)
106-114
MissingFormLabel
- 72
Pham T N, MacParland S A, Mulrooney P M et al..
Hepatitis C virus persistence after spontaneous or treatment-induced resolution of
hepatitis C.
J Virol.
2004;
78
(11)
5867-5874
MissingFormLabel
- 73
Natarajan V, Kottilil S, Hazen A et al..
HCV in peripheral blood mononuclear cells are predominantly carried on the surface
of cells in HIV/HCV co-infected individuals.
J Med Virol.
2010;
82
(12)
2032-2037
MissingFormLabel
- 74
Ramirez S, Perez-Del-Pulgar S, Carrion J A et al..
Hepatitis C virus compartmentalization and infection recurrence after liver transplantation.
Am J Transplant.
2009;
9
(7)
1591-1601
MissingFormLabel
- 75
Maggi F, Fornai C, Vatteroni M L et al..
Differences in hepatitis C virus quasispecies composition between liver, peripheral
blood mononuclear cells and plasma.
J Gen Virol.
1997;
78
(Pt 7)
1521-1525
MissingFormLabel
- 76
Revie D, Salahuddin S Z.
Human cell types important for hepatitis C virus replication in vivo and in vitro:
old assertions and current evidence.
Virol J.
2011;
8
346
MissingFormLabel
- 77
Martínez J L, Rojo F.
Metabolic regulation of antibiotic resistance.
FEMS Microbiol Rev.
2011;
35
(5)
768-789
MissingFormLabel
- 78 Klepper A, Eng F, Walewski J et al.. Contrary to published models of HCV RNA replication, heat denaturation reveals that
much of the HCV in natural infections is in double-stranded form. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 79
Jones C T, Murray C L, Eastman D K, Tassello J, Rice C M.
Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus.
J Virol.
2007;
81
(16)
8374-8383
MissingFormLabel
- 80
Pedersen I M, Cheng G, Wieland S et al..
Interferon modulation of cellular microRNAs as an antiviral mechanism.
Nature.
2007;
449
(7164)
919-922
MissingFormLabel
- 81
Chang J, Guo J T, Jiang D, Guo H, Taylor J M, Block T M.
Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic
cells.
J Virol.
2008;
82
(16)
8215-8223
MissingFormLabel
- 82
Jopling C L.
Regulation of hepatitis C virus by microRNA-122.
Biochem Soc Trans.
2008;
36
(Pt 6)
1220-1223
MissingFormLabel
- 83
Randall G, Panis M, Cooper J D et al..
Cellular cofactors affecting hepatitis C virus infection and replication.
Proc Natl Acad Sci U S A.
2007;
104
(31)
12884-12889
MissingFormLabel
- 84
Henke J I, Goergen D, Zheng J et al..
microRNA-122 stimulates translation of hepatitis C virus RNA.
EMBO J.
2008;
27
(24)
3300-3310
MissingFormLabel
- 85
Jangra R K, Yi M, Lemon S M.
Regulation of hepatitis C virus translation and infectious virus production by the
microRNA miR-122.
J Virol.
2010;
84
(13)
6615-6625
MissingFormLabel
- 86
Roberts A P, Lewis A P, Jopling C L.
miR-122 activates hepatitis C virus translation by a specialized mechanism requiring
particular RNA components.
Nucleic Acids Res.
2011;
39
(17)
7716-7729
MissingFormLabel
- 87 Sagan S, Sarnow P. Stabilization of the HCV RNA genome by miR-122. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 88 Shimakami T, Yamane D, Jangra R K et al.. miR-122 stabilizes hepatitis C virus RNA by an Ago2-dependent mechanism. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 89
Negro F.
Mechanisms of hepatitis C virus-related insulin resistance.
Clin Res Hepatol Gastroenterol.
2011;
35
(5)
358-363
MissingFormLabel
- 90
Rasmussen A L, Diamond D L, McDermott J E et al..
Systems virology identifies a mitochondrial Fatty Acid oxidation enzyme, dodecenoyl
coenzyme a delta isomerase, required for hepatitis C virus replication and likely
pathogenesis.
J Virol.
2011;
85
(22)
11646-11654
MissingFormLabel
- 91
Diamond D L, Syder A J, Jacobs J M et al..
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming
of hepatocellular metabolism and bioenergetics.
PLoS Pathog.
2010;
6
(1)
e1000719
MissingFormLabel
- 92
Berger K L, Randall G.
Potential roles for cellular cofactors in hepatitis C virus replication complex formation.
Commun Integr Biol.
2009;
2
(6)
471-473
MissingFormLabel
- 93
Estrabaud E, De Muynck S, Asselah T.
Activation of unfolded protein response and autophagy during HCV infection modulates
innate immune response.
J Hepatol.
2011;
55
(5)
1150-1153
MissingFormLabel
- 94
Ke P Y, Chen S S.
Autophagy: a novel guardian of HCV against innate immune response.
Autophagy.
2011;
7
(5)
533-535
MissingFormLabel
- 95
Ke P Y, Chen S S.
Activation of the unfolded protein response and autophagy after hepatitis C virus
infection suppresses innate antiviral immunity in vitro.
J Clin Invest.
2011;
121
(1)
37-56
MissingFormLabel
- 96 Zeuzem S, Poordad F, Gordon S C et al.. Boceprevir resistance-associated variants (RAVs) are observed more frequently in HCV
(GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin. Paper presented at: European Association for the Study of the Liver 46th Annual Meeting March 30–April 3, 2011. Berlin, Germany;
MissingFormLabel
- 97 Jiang M, Vijgen L, Sullivan J et al.. Phenotypic characterization of HCV NS3 protease from patient isolates in phase 2 clinical
trials of telaprevir. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 98
Shimakami T, Welsch C, Yamane D et al..
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired
production of infectious virus.
Gastroenterology.
2011;
140
(2)
667-675
MissingFormLabel
- 99
Kieffer T L, Sarrazin C, Miller J S et al..
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype
1 hepatitis C virus replication in patients.
Hepatology.
2007;
46
(3)
631-639
MissingFormLabel
- 100
Le Pogam S, Seshaadri A, Ewing A et al..
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents
hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected
patients.
J Infect Dis.
2010;
202
(10)
1510-1519
MissingFormLabel
- 101
Lawitz E, Nguyen T, Younes Z et al..
Valopicitabine NM283 plus PEGinterferon in treatment-naive hepatitis C patients with
HCV genotype 1 infection: HCV RNA clearance during 24 weeks of treatment.
Hepatology.
2007;
44
223A
MissingFormLabel
- 102
Ali S, Leveque V, Le Pogam S et al..
Selected replicon variants with low-level in vitro resistance to the hepatitis C virus
NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Antimicrob Agents Chemother.
2008;
52
(12)
4356-4369
MissingFormLabel
- 103
Fridell R A, Qiu D, Valera L, Wang C, Rose R E, Gao M.
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies
with the NS5A inhibitor BMS-790052.
J Virol.
2011;
85
(14)
7312-7320
MissingFormLabel
- 104
Lok A, Gardiner D, Lawitz E et al..
Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results
in 100% SVR12 in HCV genotype 1 null responders (Abstract 1356).
J Hepatol.
2011;
54
S536
MissingFormLabel
- 105
Fried M W, Hadziyannis S J, Shiffman M L, Messinger D, Zeuzem S.
Rapid virological response is the most important predictor of sustained virological
response across genotypes in patients with chronic hepatitis C virus infection.
J Hepatol.
2011;
55
(1)
69-75
MissingFormLabel
- 106
Guedj J, Bazzoli C, Neumann A U, Mentré F.
Design evaluation and optimization for models of hepatitis C viral dynamics.
Stat Med.
2011;
30
(10)
1045-1056
MissingFormLabel
- 107 Guedj J, Dahari H, Shudo E, Smith S, Perelson A. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor RG7128. Paper presented at: 18th International Symposium on Hepatitis C Virus and Related
Viruses September 8–12, 2011. Seattle, WA;
MissingFormLabel
- 108
Pearson J E, Krapivsky P, Perelson A S.
Stochastic theory of early viral infection: continuous versus burst production of
virions.
PLOS Comput Biol.
2011;
7
(2)
e1001058
MissingFormLabel
- 109
Zeuzem S, Schmidt J M, Lee J H, von Wagner M, Teuber G, Roth W K.
Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral
turnover.
Hepatology.
1998;
28
(1)
245-252
MissingFormLabel
- 110
Zeuzem S, Lee J H, Franke A et al..
Quantification of the initial decline of serum hepatitis C virus RNA and response
to interferon alfa.
Hepatology.
1998;
27
(4)
1149-1156
MissingFormLabel
- 111
Dusheiko G, Main J, Thomas H et al..
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled
study.
J Hepatol.
1996;
25
(5)
591-598
MissingFormLabel
- 112
Pawlotsky J M, Dahari H, Neumann A U et al..
Antiviral action of ribavirin in chronic hepatitis C.
Gastroenterology.
2004;
126
(3)
703-714
MissingFormLabel
- 113
Fried M W, Shiffman M L, Reddy K R et al..
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med.
2002;
347
(13)
975-982
MissingFormLabel
- 114
Manns M P, McHutchison J G, Gordon S C et al..
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin
for initial treatment of chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
(9286)
958-965
MissingFormLabel
- 115
Hézode C, Forestier N, Dusheiko G PROVE2 Study Team et al.
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
N Engl J Med.
2009;
360
(18)
1839-1850
MissingFormLabel
- 116
McHutchison J G, Everson G T, Gordon S C PROVE1 Study Team et al.
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
N Engl J Med.
2009;
360
(18)
1827-1838
MissingFormLabel
Robert RalstonPh.D.
Department of Molecular Microbiology and Immunology, School of Medicine, University
of Missouri
1201 E. Rollins Drive, Columbia, MO 65211
Email: ralstonr@missouri.edu